

Guidelines for surveillance of drug resistance in tuberculosis

5th Edition



World Health
Organization

Guidelines for surveillance of drug resistance in tuberculosis

5th Edition



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data:

Guidelines for surveillance of drug resistance in tuberculosis-- 5th ed.

1. Antitubercular Agents - pharmacology. 2. Tuberculosis, Multidrug-Resistant - epidemiology. 3. Drug Resistance. 4. Epidemiologic Surveillance - methods. 5. Guideline. I. World Health Organization.

ISBN 978 92 4 154913 4

(NLM classification: WF 360)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by Fiona Byrne
Printed in Switzerland

WHO/HTM/TB/2015.13

Table of Contents

| | |
|-------------------|-----|
| Table of Contents | iii |
| Acknowledgements | v |
| Abbreviations | vi |
| Introduction | vii |

| | |
|--|----------|
| Part I Principles of anti-tuberculosis drug resistance surveillance | 1 |
|--|----------|

| | |
|---|-----------|
| 1 Mechanisms of surveillance that produce data representative of a geographically-defined population | 3 |
| 1.1 Continuous surveillance systems based on routine drug susceptibility testing | 4 |
| 1.2 Periodic surveys for estimating the burden of drug resistance | 4 |
| 1.3 Sentinel surveillance systems for monitoring trends over time | 5 |
| 2 Standardized stratification of results by patient characteristics | 6 |
| 2.1 Patient treatment history classifications | 6 |
| 2.2 Age groups, sex, HIV status and other patient biographical and clinical factors | 7 |
| 3 Quality-assured laboratory methods for determining resistance to first- and second-line drugs | 9 |
| 3.1 WHO-recommended methods of drug susceptibility testing | 9 |
| 3.2 Selection of drugs to be tested for susceptibility | 11 |
| 3.3 Quality assurance of drug susceptibility testing | 11 |
| 4 Ethical considerations | 14 |

| | |
|---|-----------|
| Part II Conducting surveys for assessing the proportion of anti-TB drug resistance | 17 |
|---|-----------|

| | |
|---|-----------|
| 5 Survey planning | 19 |
| 5.1 Forming a national coordination team | 19 |
| 5.2 Setting objectives | 19 |
| 5.3 Defining the diagnostic testing algorithm | 20 |
| 5.4 Development of a protocol and time schedule | 21 |
| 5.5 Minimum required facilities for a survey area | 21 |
| 5.6 Sampling of cases | 22 |

| | | |
|---|---|-----------|
| 5.7 | Budgeting | 29 |
| 5.8 | Training | 30 |
| 5.9 | Laboratory preparedness | 30 |
| 5.10 | Pilot study | 31 |
| 6 | Survey logistics | 32 |
| 6.1 | Inclusion and exclusion criteria | 32 |
| 6.2 | Patient intake | 33 |
| 6.3 | Sputum collection, processing and transport | 34 |
| 6.4 | Laboratory methods | 35 |
| 6.5 | Monitoring and evaluation | 37 |
| 7 | Survey data management and analysis | 39 |
| 7.1 | Data management | 39 |
| 7.2 | Data analysis | 40 |
| 7.3 | Interpretation of results | 43 |
| <hr/> Part III Sentinel surveillance for monitoring trends over time | | 45 |
| 8 | Designing a sentinel system | 47 |
| 8.1 | Setting objectives | 47 |
| 8.2 | Defining the diagnostic testing algorithm | 47 |
| 8.3 | Sampling of cases | 47 |
| References | | 49 |
| <hr/> Annexes | | |
| Annex 1 - Approaches for countries without capacity for continuous surveillance | | 51 |
| Annex 2 - Drug resistance survey protocol checklist | | 52 |
| Annex 3 - Flowchart of enrolled patients | | 56 |
| Annex 4 - Results summary tables | | 57 |
| Annex 5 - Survey budget template | | 59 |
| Annex 6 - Example of a clinical information form | | 61 |
| Annex 7 - Safe shipment of infectious material | | 63 |

Acknowledgements

This updated edition was written by Anna Dean and Matteo Zignol.

Development of this document was guided by the following panel of external experts and staff of the World Health Organization (WHO):

External experts: Daniela Cirillo (San Raffaele Scientific Institute, Milan, Italy), Frank Cobelens (KNCV Tuberculosis Foundation, The Hague, The Netherlands), Ted Cohen (Yale School of Public Health, New Haven, United States), Charlotte Colvin (United States Agency for International Development (USAID), Washington DC, United States), Julia Ershova (Centers for Disease Prevention and Control, Atlanta, United States), Aleksandr Golubkov (USAID, Washington DC, United States), Arax Hovhannesian (World Vision Armenia, Yerevan, Armenia), Maeve Lalor (Public Health England, London, United Kingdom), Fulvia Mecatti (University of Milan-Bicocca, Milan, Italy), Patrick Moonan (Centers for Disease Prevention and Control, Atlanta, United States), Amy Pietak (USAID, Washington DC, United States), Michael Selgelid (Australian National University, Canberra, Australia), Susan van den Hof (KNCV Tuberculosis Foundation, The Hague, The Netherlands), Marieke van der Werf (European Centre for Disease Prevention and Control, Stockholm, Sweden), Armand Van Deun (Institute of Tropical Medicine, Antwerp, Belgium) and Norio Yamada (Research Institute of Tuberculosis, Tokyo, Japan)

WHO staff: Annabel Baddeley, Samiha Baghdadi, Andrei Dadu, Dennis Falzon, Katherine Floyd, Christopher Gilpin, Philippe Glaziou, Tauhidul Islam, Knut Lonnroth, Alberto Matteelli, Wilfred Nkhoma, Andreas Reis, Charalambos Sismanidis and Karin Weyer, under the direction of Mario Raviglione

Portions of this updated edition are based on materials developed by Abigail Wright and Wayne van Gemert (WHO).

Production of this document was supported by a financial contribution from USAID.

Abbreviations

| | |
|----------------|--|
| CPC | cetylpyridinium chloride |
| DST | drug susceptibility testing |
| Global Project | Global Project on Anti-Tuberculosis Drug Resistance Surveillance |
| LPA | line probe assay |
| MAR | missing at random |
| MDR-TB | multidrug-resistant tuberculosis |
| NAAT | new nucleic acid amplification tests |
| PPS | probability proportional to size |
| SRL | Supranational Reference Laboratory |
| SRLN | Supranational Reference Laboratory Network |
| TB | tuberculosis |
| USAID | United States Agency for International Development |
| XDR-TB | extensively drug-resistant tuberculosis |

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27401

